TITLE

Gastrointestinal complications of HIV infection: changing priorities in the HAART era

AUTHOR(S)
Wilcox, C. M.; Saag, M. S.
PUB. DATE
June 2008
SOURCE
Gut;Jun2008, Vol. 57 Issue 6, p861
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
It has now been some 25 years since the initial description of AIDS. Following these observations, the epidemiology, natural history and manifestations of this disease have been well characterised. Intense investigation has better characterised HIV, resulting in the development of effective drug therapies to arrest disease progression. These multidrug combinations, termed highly active antiretroviral therapy or HAART, can suppress the viral load to the undetectable range and secondarily halt the destruction of CD4 T lymphocytes. This virological response is associated with a marked improvement in survival and absence of the many complications related to immunodeficiency. For patients who respond to HAART, the current emphasis is on treating side effects from the medications as well as treating other non-AIDS-related disorders. However, given the cost and complexities of these regimens, there are many patients who continue to present with the classic manifestations of AIDS, and, especially in the developing world, we wilt continue to see these patients for years to come.
ACCESSION #
32531223

 

Related Articles

  • USEFULNESS OF HEMOGLOBIN AND ALBUMIN AS PROGNOSTIC MARKERS FOR HIGHLY ACTIVE ANTIRETROVIRAL THERAPY FOR HIV-1 INFECTION. CHAUHAN, NEERAJ K.; VAJPAYEE, MADHU; SINGH, ALPANA // Indian Journal of Medical Sciences;Jul2011, Vol. 65 Issue 7, p286 

    BACKGROUND: Usefulness of hemoglobin and albumin as prognostic markers for highly active anti-retroviral therapy for HIV-1 infection. INTRODUCTION: Anemia and hypoalbuminemia are common complications in human immunodeficiency virus (HIV) infection. We aimed to investigate the changes in...

  • Case of relapsed AIDS-related plasmablastic lymphoma treated with autologous stem cell transplantation and highly active antiretroviral therapy. Goto, Hiroki; Hagiwara, Shotaro; Hirai, Risen; Miyama, Takahiko; Honda, Haruhito; Tagashira, Amane; Iizuka, Toshihiko; Mochizuki, Makoto; Teruya, Katsuji; Kikuchi, Yoshimi; Oka, Shinichi; Miwa, Akiyoshi // Rare Tumors;2011, Vol. 3 Issue 1, p33 

    Plasmablastic lymphoma is a rare and aggressive malignancy strongly associated with HIV infection. The refractory/relapsed disease rate is high, and the survival rate is characteristically poor. There are no satisfactory salvage regimens for relapsed cases. We successfully performed autologous...

  • CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. Huabiao Chen; Chun Li; Jinghe Huang; Thai Cung; Seiss, Katherine; Beamon, Jill; Carrington, Mary F.; Porter, Lindsay C.; Burke, Patrick S.; Yu Yang; Ryan, Bethany J.; Ruiwu Liu; Weiss, Robert H.; Pereyra, Florencia; Cress, William D.; Brass, Abraham L.; Rosenberg, Eric S.; Walker, Bruce D.; Yu, Xu G.; Lichterfeld, Mathias // Journal of Clinical Investigation;Apr2011, Vol. 121 Issue 4, p1549 

    Elite controllers represent a unique group of HIV-1-infected persons with undetectable HIV-1 replication in the absence of antiretroviral therapy. However, the mechanisms contributing to effective viral immune defense in these patients remain unclear. Here, we show that compared with HIV-1...

  • Cytomegalovirus retinitis in patients with HIV a significant global problem. Boyle, Erin L.; Bechtel, Bryan; Hasson, Matt; Master, Joe; Mullin, David W. // Ocular Surgery News;11/25/2010, Vol. 28 Issue 22, p16 

    No abstract available.

  • Duration of Fecal Shedding of Shiga Toxin–Producing Escherichia coli O104:H4 in Patients Infected During the 2011 Outbreak in Germany: A Multicenter Study. Vonberg, Ralf P.; Höhle, Michael; Aepfelbacher, Martin; Bange, Franz C.; Belmar Campos, Cristina; Claussen, Katja; Christner, Martin; Cramer, Jakob P.; Haller, Hermann; Hornef, Mathias; Fickenscher, Helmut; Fraedrich, Katharina; Knobloch, Johannes K.; Kühbacher, Tanja; Manns, Michael P.; Nitschke, Martin; Peters, Georg; Pulz, Matthias; Rohde, Holger; Roseland, Rahel T. // Clinical Infectious Diseases;Apr2013, Vol. 56 Issue 8, p1132 

    Median Shiga toxin–producing Escherichia coli STEC O104:H4 shedding duration was 17–18 days (13–14 days in hemolytic uremic syndrome patients vs 33–34 days in others). Shedding duration was reduced after antimicrobial treatment, prolonged in patients ≤15 years,...

  • Experiences and Perceptions of Patients with 100% Adherence to Highly Active Antiretroviral Therapy: A Qualitative Study. Sidat, Mohsin; Fairley, Christopher; Grierson, Jeffrey // AIDS Patient Care & STDs;Jul2007, Vol. 21 Issue 7, p509 

    A decade has passed since the introduction of highly active antiretroviral therapy (HAART) as standard of care for HIV/AIDS patients. The success of HAART is largely dependent on almost 100% adherence to it. In this study our primary aim was to understand from patients' own perspectives and...

  • Role of human cytomegalovirus genotype polymorphisms in AIDS patients with cytomegalovirus retinitis. Vogel, Jens-Uwe; Otte, Jürgen; Koch, Frank; Gümbel, Hermann; Doerr, Hans; Cinatl, Jindrich // Medical Microbiology & Immunology;Feb2013, Vol. 202 Issue 1, p37 

    Although several host factors have been identified to influence the course of HCMV infection, it still remains unclear why in AIDS patients without highly active antiretroviral therapy human cytomegalovirus (HCMV) retinitis is one of the most common opportunistic infections, whereas in other...

  • Restoration of T Cell Responses to Toxoplasma gondii after Successful Combined Antiretroviral Therapy in Patients with AIDS with Previous Toxoplasmic Encephalitis. Lejeune, Marylène; Miró, José M.; De Lazzari, Elisa; Garc, Felipe; Claramonte, Xavier; Martínez, Esteban; Ribera, Esteban; Arrizabalaga, Julio; Arribas, José R.; Domingo, Pere; Ferrer, Elena; Plana, Montserrat; Valls, María-Eugenia; Podzamczer, Daniel; Pumarola, Tomás; Jacquet, Alain; Mallolas, Josep; Gatell, José M.; Gallart, Teresa // Clinical Infectious Diseases;3/1/2011, Vol. 52 Issue 5, p662 

    Background. It is unknown whether a Toxoplasma gondii-specific T cell response is restored after successful combined antiretroviral therapy (cART) in patients with AIDS and current or previous toxoplasmic encephalitis (TE). Methods. We performed a multicenter cross-sectional study with 17...

  • Incidence and determinants of new AIDS-defining illnesses after HAART initiation in a Senegalese cohort. De Beaudrap, Pierre; Etard, Jean-François; Diouf, Assane; Ndiaye, Ibrahima; Ndèye, Guèye Fatou N.; Sow, Papa S.; Ndèye, Kane Coumba T.; Ecochard, René; Delaporte, Eric // BMC Infectious Diseases;2010, Vol. 10 Issue 1, p179 

    Background: Although a dramatic decrease in AIDS progression has been observed after Highly Active Anti Retroviral Therapy (HAART) in both low- and high-resource settings, few data support that fact in low-resource settings. This study describes the incidence of AIDS-defining illnesses (ADI)...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics